Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact
Banner

Shorla Oncology attending Jefferies Healthcare Conference

October 31st 2023

Read More

Logo

PRESS RELEASE: Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind

October 31st 2023

Read More

Logo

Goodman-backed Shorla Oncology secures $35m in Series-B funding

October 24th 2023

Read More

Logo

Shorla Oncology raises $35m to accelerate growth

October 24th 2023

Read More

Photo

Raising Funds in a Tight Market: Q&A With Sharon Cunningham, CEO of Shorla Oncology

October 24th 2023

Read More

Logo

Shorla Oncology at BIO-Europe 2023

October 20th 2023

Read More

Logo

Shorla Oncology at CPhI Barcelona 2023

October 10th 2023

Read More

Banner

PRESS RELEASE: Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio

October 4th 2023

Read More

Banner

Women Of The Year 2023 Awards Nomination

September 28th 2023

Read More

Older posts
Newer posts
Page1 … Page5 Page6 Page7 … Page10
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

STATE COMPLIANCE PROGRAM DECLARATIONS

Company number: 618033
©SHORLA ONCOLOGY® 2026

© 2026 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.